NASDAQ:ONXX - Onyx Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).

Receive ONXX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:ONXX
CUSIP68339910
WebN/A
Phone+1-650-2660000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Onyx Pharmaceuticals (NASDAQ:ONXX) Frequently Asked Questions

What is Onyx Pharmaceuticals' stock symbol?

Onyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ONXX."

Has Onyx Pharmaceuticals been receiving favorable news coverage?

News coverage about ONXX stock has been trending positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Onyx Pharmaceuticals earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.

What other stocks do shareholders of Onyx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onyx Pharmaceuticals investors own include Michael Kors (KORS), Nike (NKE), Perrigo (PRGO), First Solar (FSLR), salesforce.com (CRM), VMware (VMW), Stratasys (SSYS), Alphabet (GOOG), Tesla (TSLA) and Morgan Stanley (MS).

How do I buy shares of Onyx Pharmaceuticals?

Shares of ONXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Onyx Pharmaceuticals?

Onyx Pharmaceuticals' mailing address is 249 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4804, United States. The biopharmaceutical company can be reached via phone at +1-650-2660000.


MarketBeat Community Rating for Onyx Pharmaceuticals (NASDAQ ONXX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  303 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  535
MarketBeat's community ratings are surveys of what our community members think about Onyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ONXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel